Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rigel Pharmaceuticals (RIGL)
:RIGL
Holding RIGL?
Track your performance easily
RIGL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.48 - $29.82
Previous CloseN/A
Volume99.93K
Average Volume (3M)284.84K
Market Cap
$305.62M
Enterprise Value$284.66M
Total Cash (Recent Filing)$74.77M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)80.1
Beta2.07
Next Earnings
Feb 27, 2025EPS Estimate
0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.22
Shares Outstanding17,615,040
10 Day Avg. Volume221,757
30 Day Avg. Volume284,838
Standard Deviation0.28
R-Squared0.06
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.01
Price to Cash Flow (P/CF)3.70
P/FCF Ratio3.30
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue1.81
Enterprise Value/Gross Profit2.59
Enterprise Value/Ebitda20.83
Forecast
1Y Price Target
$34.80Price Target Upside100.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Rigel News
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementPhase 1b trial of R289 shows promising responses and favorable safety profile in patients with lower-risk myeloid dysplastic syndrome.
Financial PerformanceRigel reported strong growth across its commercial portfolio, with net sales reaching $38.9 million, a 44% increase compared to $27.1 million previously.
Strategic PartnershipRigel announced an exclusive license and supply agreement with Kissei Pharmaceuticals for the development and commercialization of Rezlidhia in Japan, the Republic of Korea, and Taiwan.
Bears Say
Adverse EffectsFatal infections were reported in five patients taking Gavreto, whereas no such cases occurred in the standard care group.
Drug Safety ConcernsA new safety signal for Gavreto has been identified, indicating an increased risk of severe infections.
Health RisksAn analysis showed a higher rate of severe and fatal infections among patients using Gavreto compared to those receiving standard care.
---
Ownership Overview
20.18% Insiders
25.25% Mutual Funds
2.33% Other Institutional Investors
41.69% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RIGL FAQ
What was Rigel Pharmaceuticals’s price range in the past 12 months?
Rigel Pharmaceuticals lowest stock price was $7.48 and its highest was $29.82 in the past 12 months.
What is Rigel Pharmaceuticals’s market cap?
Rigel Pharmaceuticals’s market cap is $305.62M.
When is Rigel Pharmaceuticals’s upcoming earnings report date?
Rigel Pharmaceuticals’s upcoming earnings report date is Feb 27, 2025 which is in 40 days.
How were Rigel Pharmaceuticals’s earnings last quarter?
Rigel Pharmaceuticals released its earnings results on Nov 07, 2024. The company reported $0.7 earnings per share for the quarter, beating the consensus estimate of $0.058 by $0.642.
Is Rigel Pharmaceuticals overvalued?
According to Wall Street analysts Rigel Pharmaceuticals’s price is currently Undervalued.
Does Rigel Pharmaceuticals pay dividends?
Rigel Pharmaceuticals does not currently pay dividends.
What is Rigel Pharmaceuticals’s EPS estimate?
Rigel Pharmaceuticals’s EPS estimate is 0.45.
How many shares outstanding does Rigel Pharmaceuticals have?
Rigel Pharmaceuticals has 17,615,040 shares outstanding.
What happened to Rigel Pharmaceuticals’s price movement after its last earnings report?
Rigel Pharmaceuticals reported an EPS of $0.7 in its last earnings report, beating expectations of $0.058. Following the earnings report the stock price went up 42.94%.
Which hedge fund is a major shareholder of Rigel Pharmaceuticals?
Among the largest hedge funds holding Rigel Pharmaceuticals’s share is Graham Capital Management, L.P.. It holds Rigel Pharmaceuticals’s shares valued at 0.
---
Rigel Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$34.80 (100.58% Upside)
$34.80 (100.58% Upside)
Blogger Sentiment
Bullish
RIGL Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 3.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.57%
12-Months-Change
Fundamentals
Return on Equity
-26.52%
Trailing 12-Months
Asset Growth
20.89%
Trailing 12-Months
Company Description
Rigel Pharmaceuticals
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. Its products include Tavalisse, Fostamatinib and R835. The company was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.
---
RIGL Company Deck
---
RIGL Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
Rigel Pharmaceuticals reported strong financial performance with significant revenue growth and international expansion. The addition of GAVRETO contributed positively, although there were minor challenges in transitioning certain accounts. Overall, the company achieved positive net income, marking a successful quarter.Read More>---
RIGL Stock 12 Month Forecast
Average Price Target
$34.80
▲(100.58% Upside)
Technical Analysis
Aurinia Pharmaceuticals
―
Aldeyra Therapeutics
―
Fate Therapeutics
―
BioCryst
―
Adaptimmune Therapeutics
―
Mersana Therapeutics
―
Best Analysts Covering RIGL
1 Year
1 Year Success Rate
11/13 ratings generated profit
1 Year Average Return
+44.91%
reiterated a buy rating 4 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 84.62% of your transactions generating a profit, with an average return of +44.91% per trade.
---